NCT00674583已完成3 期
Non-inferiority of GSK Biologicals' Meningococcal Vaccine (GSK134612) Compared to Licensed MenC-CRM197 Conjugate Vaccine in Healthy Children
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 414
- 试验地点
- 32
- 主要终点
- Number of Subjects With Vaccine Response to Meningococcal Serogroup C Serum Based on a Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody
研究概览
简要总结
The purpose of the study is to investigate whether or not GSK Biologicals' meningococcal vaccine GSK134612 is inferior to a licensed MenC-CRM197 conjugate vaccine in terms of vaccine antibody response against meningococcal serogroup C disease.
详细描述
The study has 2 study groups. One group will receive one dose of GSK Biologicals' vaccine GSK 134612 and the other group will receive one dose of licensed MenC-CRM197 vaccine. All subjects will have 2 blood samples taken: just before vaccination and one month after vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects whose parents/guardians, the investigator believes can and will comply with the requirements of the protocol.
- •A male or female between, and including, 2 and 10 years of age at the time of the vaccination.
- •Written informed consent obtained from the parent(s) or guardian of the subject.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge.
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the study vaccine dose, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose..
- •Administration of a vaccine not foreseen by the study protocol during the period starting from one month before the dose of the study vaccine and ending 30 days after.
- •Concurrently participating in another clinical study or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C W-135 and/or Y (for subjects below 6 years) or within the last five years (for subjects 6 years old and above).
- •Previous vaccination with meningococcal polysaccharide conjugate vaccine serogroups A, C, W-135 and/or Y.
- •History of meningococcal disease.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.
- •A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •History of any neurologic disorders or seizures.
- •Acute disease at the time of enrolment
- •Administration of immunoglobulins and/or any blood products within the three months preceding the study vaccine dose or planned administration during the study period.
- •Exclusion criteria for specified regions in France
- •Subjects in contact with somebody suffering from an invasive infection with meningococcal serogroups A, C, Y or W-135, or
- •Subjects living in a geographic area in France where local outbreak with meningococcal serogroup C has occurred and would thus be likely to participate in a vaccination campaign against meningococcal serogroup C.
结局指标
主要结局
Number of Subjects With Vaccine Response to Meningococcal Serogroup C Serum Based on a Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody
时间窗: One month after vaccination (Month 1)
Vaccine response to MenC was defined as: -for initially seronegative subjects \[i.e. rSBA-MenC titer below (\<) 1:8\], antibody titer greater than or equal to (≥) 1:32; -for initially seropositive (i.e. rSBA-MenC titer ≥ 1:8), antibody titer post-vaccination ≥ 4-fold the pre-vaccination antibody titer.
次要结局
- Number of Subjects Between 2 and 5 Years of Age With Any and Grade 3 Solicited Local Symptoms(During the 4-day (Days 0-3) post-vaccination period)
- Anti-meningococcal Serogroup Polysaccharides (Anti-PS) Antibody Concentrations(Prior to (Month 0) and one month after vaccination (Month 1))
- Number of Subjects Between 6 and 10 Years of Age With Any and Grade 3 Solicited Local Symptoms(During the 4-day (Days 0-3) post-vaccination period)
- Number of Subjects With Any Serious Adverse Events (SAEs)(Up to six months after vaccination (Month 6))
- Meningococcal Serogroup A (rSBA) Antibody Titers by Serogroup(Prior to (Month 0) and one month after vaccination (Month 1))
- Number of Subjects Between 2 and 5 Years of Age With Any, Grade 3 and Related Solicited General Symptoms(During the 4-day (Days 0-3) post-vaccination period)
- Number of Subjects Reporting Specific Adverse Events(Up to 6 months after vaccination (Month 6))
- Number of Subjects Between 6 and 10 Years of Age With Any, Grade 3 and Related Solicited General Symptoms(During the 4-day (Days 0-3) post-vaccination period)
- Number of Subjects With Any Unsolicited Adverse Events (AEs)(During the 31-day (Days 0-30) post-vaccination period)
研究者
研究点 (32)
Loading locations...
相似试验
已完成
3 期
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612Infections, MeningococcalNCT00465816GlaxoSmithKline611
已完成
3 期
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsInfections, MeningococcalNCT01755689GlaxoSmithKline1,300
已完成
3 期
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesInfections, MeningococcalMeningococcal VaccinesNCT01144663GlaxoSmithKline2,095
已完成
3 期
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old SubjectsInfections, MeningococcalMeningococcal VaccinesNCT00514904GlaxoSmithKline1,504
已完成
3 期
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood CancersHerpes ZosterNCT01767467GlaxoSmithKline568